Psychiatric medications and bowel disease activity: associations with important gaps
A review linked several medications with improved inflammatory bowel disease measures. Limited data, differing studies and missing comparison details prevent a clear estimate of benefit.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In people with inflammatory bowel disease, several psychiatric medications were associated with improved measures of bowel disease activity. The review highlighted antidepressants, naltrexone and clonidine, but its studies differed and included case reports. These findings concern gastrointestinal outcomes; they do not establish that treating psychiatric symptoms reliably improves bowel inflammation or that every medication has the same effect.
The abstract does not describe study-specific comparators, follow-up times or effect sizes. Its authors explicitly note limited data and differences among studies, leaving the size and certainty of any benefit unresolved.
What did disease activity mean?
The review examined measures of symptoms and bowel disease activity, including clinical scores and scores from examinations inside the bowel. These outcomes should be distinguished from improvements in depression, anxiety or other psychiatric symptoms.
How consistent was the medication evidence?
Some findings came from individual case reports, including reports concerning pregabalin and lithium carbonate. Topiramate showed limited efficacy. This varied evidence does not support treating the medications as interchangeable or assuming a benefit across all drug classes.
The original publication
Psychopharmacological Therapy Positively Modulates Disease Activity in Inflammatory Bowel Disease: A Systematic Review.
Di Vincenzo F, D'Onofrio AM, Del Gaudio A et al.
Int J Mol Sci · 2025
- PubMed ID
- 40650291
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.